Video
Dr. Shore on the benefits of starting darolutamide for patients with nmCRPC
Author(s):
Video Player is loading.
In this video, Neal D. Shore, MD, FACS, advises clinicians to counsel their patients with nmCRPC about starting the darolutamide (Nubeqa) regimen, as it has many benefits that will improve their quality of life. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina.
Related Videos
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Related Content
